Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

BIO-RAD LABORATORIES, INC.
Next earnings Jul 29, 2026 (after close) · consensus $1.77 EPS, $630M rev
Last earnings +1.8% on 2026-04-30
Cheap on headline 10.1x P/E, but flat revenue and a thin 1.8% operating margin make BIO a value-trap hold.
Sources: SEC EDGAR (CIK 0000012208, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 8:44:55 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Middling fundamentals offset by an attractive price (~275% below fair value) — worth a look on the value angle.
Bio-Rad screens optically cheap at a 10.1x P/E on FY2025 diluted EPS of $27.85, and the balance sheet is fortress-grade: $7.45B of equity against just $3.12B of total liabilities (0.42x liabilities/equity), $530M of cash, and $1.20B of long-term debt that barely moved year over year. Net income swung to $760M (+141.2%) and the company keeps returning capital, with share buybacks rising to $296M. On the surface this is a high-quality, well-capitalized franchise trading at a single-digit earnings multiple.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Operating income | $500M | $483M | $338M | $269M | $47.2M |
| Net income | $4.25B | -$3.63B | -$637M | -$1.84B | $760M |
| Diluted EPS | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 |
| Net margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1482 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 1 sale
| 2026-05-11 | ENGELHARDT EVA ANETTE EVP, President, CDG | Sell | 550.00 @ $246.54 | $136K |
| 2026-04-24 | Lakkaraju Roop Kalyan EVP, Chief Financial Officer | Exercise | 1.08K | |
| 2026-04-24 | Lakkaraju Roop Kalyan EVP, Chief Financial Officer | Tax | 420.00 @ $287.84 | $121K |
| 2026-04-24 | ENLOE COURTNEY C EVP, General Counsel & Sec | Exercise | 186.00 | |
| 2026-04-24 | ENLOE COURTNEY C EVP, General Counsel & Sec | Tax | 77.00 @ $287.84 | $22.2K |
| 2026-04-21 | Hinckley Greg K Director | Exercise | 407.00 | |
| 2026-04-21 | PEI MELINDA LITHERLAND Director | Exercise | 407.00 | |
| 2026-04-21 | EDWARDS JEFFREY L Director | Exercise | 407.00 | |
| 2026-04-21 | PINKSTON ARNOLD A Director | Exercise | 407.00 | |
| 2025-11-06 | BARRY JAMES EVP, President, LSG | Sell | 699.87 @ $306.18 | $214K |